[18] Other research suggests that several pharmaceutical companies, including AstraZeneca, Zealand Pharma, Roche, and Amgen, are expected to enter the GLP-1 market, with multiple drug launches planned between 2027 and 2032
But the null finding is notable because it suggests that GLP-1 appetite suppression may already be near the ceiling of what appetite reduction can achieve, leaving little room for phentermine to add benefit
It can also cause a paralysis of the facial nerve, known as Ramsay Hunt syndrome
Along with chronic stress, several factors drive up our cortisol levelsand those higher levels are thought to contribute to the tendency to gain weight disproportionately around the midriff
This FDA-approved medication delivers impressive results, with patients losing an average of 10.9% of their total body weight in just 6 months
I hope that professional colleagues can understand why the label has been made for medullary thyroid cancer